Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (361-370 of 607) with videos related to

Pageof 61
Sort By:
Arthritis Research & Therapy|July 18, 2024
Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA studyPanagiota Xanthouli, Paul Uesbeck, Hanns-Martin Lorenz, et al.
European Heart Journal|May 10, 2006
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertensionMark H Williams, Clive E Handler, Raza Akram, et al.
Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [And] International Society for Digital Imaging of Skin (ISDIS) [And] International Society for Skin Imaging (ISSI)|July 24, 2009
Validation of a protocol for the assessment of skin temperature and blood flow in childhood localised sclerodermaKevin J Howell, Antonia Lavorato, María Teresa Visentin, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
The Lancet. Rheumatology|January 22, 2024
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolutionGemma Lepri, Michael Hughes, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|July 6, 2023
Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosisChristopher P Denton, Shiwen Xu, Fenge Zhang, et al.
Annals of the Rheumatic Diseases|March 11, 2019
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohortWanlong Wu, Suzana Jordan, Nicole Graf, et al.
Rheumatology (Oxford, England)|October 14, 2024
Self-reported skin severity and quality of life in systemic sclerosis: multicentre validation of PASTULJulia Spierings, Paco M J Welsing, Seda Colak, et al.
Arthritis and Rheumatism|July 11, 2013
Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertensionEmma C Derrett-Smith, Audrey Dooley, Adrian J Gilbane, et al.
Annals of the Rheumatic Diseases|June 23, 2019
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysisMike Becker, Nicole Graf, Rafael Sauter, et al.
Pageof 61

Showing results (361-370 of 607) with videos related to

Sort By:
Pageof 61
Arthritis Research & Therapy|July 18, 2024
Effect of ambrisentan in patients with systemic sclerosis and mild pulmonary arterial hypertension: long-term follow-up data from EDITA studyPanagiota Xanthouli, Paul Uesbeck, Hanns-Martin Lorenz, et al.
European Heart Journal|May 10, 2006
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertensionMark H Williams, Clive E Handler, Raza Akram, et al.
Skin Research and Technology : Official Journal of International Society for Bioengineering and the Skin (ISBS) [And] International Society for Digital Imaging of Skin (ISDIS) [And] International Society for Skin Imaging (ISSI)|July 24, 2009
Validation of a protocol for the assessment of skin temperature and blood flow in childhood localised sclerodermaKevin J Howell, Antonia Lavorato, María Teresa Visentin, et al.
JAMA|May 11, 2016
Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis: DUAL-1 and DUAL-2 Randomized Clinical TrialsDinesh Khanna, Christopher P Denton, Peter A Merkel, et al.
The Lancet. Rheumatology|January 22, 2024
The role of skin ultrasound in systemic sclerosis: looking below the surface to understand disease evolutionGemma Lepri, Michael Hughes, Yannick Allanore, et al.
Annals of the Rheumatic Diseases|July 6, 2023
Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosisChristopher P Denton, Shiwen Xu, Fenge Zhang, et al.
Annals of the Rheumatic Diseases|March 11, 2019
Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohortWanlong Wu, Suzana Jordan, Nicole Graf, et al.
Rheumatology (Oxford, England)|October 14, 2024
Self-reported skin severity and quality of life in systemic sclerosis: multicentre validation of PASTULJulia Spierings, Paco M J Welsing, Seda Colak, et al.
Arthritis and Rheumatism|July 11, 2013
Endothelial injury in a transforming growth factor β-dependent mouse model of scleroderma induces pulmonary arterial hypertensionEmma C Derrett-Smith, Audrey Dooley, Adrian J Gilbane, et al.
Annals of the Rheumatic Diseases|June 23, 2019
Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysisMike Becker, Nicole Graf, Rafael Sauter, et al.
Pageof 61